Latest News for: psvt

Edit

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT (Form 8-K) (Milestone Pharmaceuticals Inc)

Public Technologies 20 Mar 2026
· Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo ... of CARDAMYST for the treatment of PSVT.
Edit

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by ...

Nasdaq Globe Newswire 06 Jan 2026
... nasal spray, developed to be the first rapid, reliable option in the treatment of paroxysmal supraventricular tachycardia (PSVT) outside of the healthcare setting.
Edit

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency (Form 8-K) (Milestone Pharmaceuticals Inc)

Public Technologies 06 Jan 2026
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - A European decision on approval is expected by Q1 2027.
Edit

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Pharmiweb 18 Dec 2025
Novel treatment for PSVT developed with Milestone Pharmaceuticals ... Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
  • 1

Article Search

tools
×
×
×
×